XLON
TSTL
Market cap278mUSD
Aug 24, Last price
427.50GBP
1D
0.59%
1Q
11.91%
Jan 2017
174.04%
IPO
856.12%
Name
Tristel PLC
Chart & performance
P/E
30.90
P/S
4.42
EPS
0.14
Div yield, %
3.34%
Shrs. gr., 5y
0.49%
Rev. gr., 5y
7.96%
Revenues
46m
+10.80%
Net income
7m
+2.33%
CFO
10m
-5.24%
Dividend
Mar 19, 20265.68 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating both within the United Kingdom and globally, Tristel plc specializes in the development, production, and distribution of products designed for infection control. Its business is structured into three primary divisions: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and a third, unnamed 'Other' segment. Under its proprietary Tristel brand, the firm provides a comprehensive range of medical instrument disinfection solutions. These cater to a diverse array of applications, such as airway management, cardiology, ENT, endoscopy, gastrointestinal physiology, laboratory use, ophthalmology, phlebotomy, reproductive health/IVF, surface disinfection, ultrasound, urology, and women's health, alongside other related offerings. Established in 1993, Tristel plc maintains its headquarters in Snailwell, United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||